Biora Therapeutics, Inc. (BIOR) Tops Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2022 Financial Results
August 15, 2022 4:06 PM EDTSuccessfully completed PM-602 human study for its targeted therapeutics platform demonstrating
promising device performance in active ulcerative colitis patients
Successfully completed PM-611 human study for its targeted therapeutics platform in healthy volunteers
showing promising performance regardless of feeding schedule
Confirmed planned phase 1 IND filing in Q1 based on FDA feedback on PGN-600 program in ulcerative
colitis
Strengthened patent position for both targeted and systemic therapeutics platforms
Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM... More
